Virtual poster abstractsResults: There were 86 cases with fetal CAKUT, median gestational age at diagnosis was 22 weeks and at termination was 38 weeks. Hydronephrosis 52 (60.4%) was the most common CAKUT observed followed by parenchymal diseases 24 (27.9%) and Left kidney (54%) was more often affected in unilateral cases. None of the fetuses with (6.9%) Bilateral renal agenesis survived. Low survival rate was observed for bilateral parenchymal diseases (24 cases), 14 (16.2%) of which had abortion or intrauterine/neonatal death. Significant association observed between right and left kidney size, right and left parenchyma measurements, bladder size and AFI with outcome of pregnancy. Associated anomalies were present in 23 (26.7%) cases. In 51 live babies followed up post-natally, spontaneous resolution was seen in 16 (31.4%), 18 (35.2%) were unresolved but asymptomatic while 17 (33.3%) required treatment with surgical intervention done for 8 cases (15.6%). Conclusions: Severe CAKUT diagnosed in earlier gestation has poor outcome, non-obstructive hydronephrosis has good prognosis compared to obstructive type, parenchymal disease is associated with poor outcome while unilateral CAKUT is associated with good outcome. Amniotic fluid index, associated anomalies and ultrasound parameters like size of kidneys, anteroposterior diameter of pelvis, parenchymal thickness influences the prognosis. VP12.05 Prenatal diagnosis of the vaginal and urethral polyps
3rd trimester ultrasound and birthweight equal or above 30 percentiles. We included singleton-pregnancies with EFW≥p40 on the ultrasound performed in our centre, that delivered after 34 weeks. Electronic fetal monitoring was performed throughout all labour, and whenever asked regional analgesia. The primary outcome was the need of instrumental or Caesarean delivery due to non-reassuring fetal status (NRFS). Secondary outcomes were: neonatal intensive care unit (NICU) admission; Apgar score at 5th minute <7; fetal death or neonatal death. Results: During the study period, 90 cases met the inclusion criteria: 17 cases in the study group and 73 cases in the control group. Median percentile at 3rd trimester ultrasound was 62 (40-98) and birth occurred at 39 (35.4-41.5) weeks. Median percentile at birth was 60 (1-100). Although it was not significantly different, the needed for instrumental or Caesarean delivery for NRFS was higher in the decelerated growth group (p-value 0.451). There were no differences between groups regarding secondary outcomes. Conclusions: In our study, decelerated growth was not associated with adverse perinatal outcomes. The small sample and its retrospective nature are the main limitations of our study. VP36.
Virtual poster abstractsResults: Over the period of 2 years six cases of FIUVV were diagnosed making the incidence of FIUVV of 5/10000 pregnancies. Incidence of isolated FIUVV was 4.4/10000 cases. The mean gestational age at diagnosis was 25 weeks 3days with earliest diagnosis at 19w1d. Aneuploidy screening was done in five of cases with low risk for trisomy 21, 18 & 13 as outcome. The mean varix size was 11.85mm±2.28 mm (range 8.9mm-14.8 mm). No incidence of turbulence or thrombus formation within the varix was seen in the current study. One case had absent DV with anomalous connection of umbilical vein with IVC. One Perinatal death after planned LSCS at term & sudden IUFD at 33 weeks were noted in this study. Conclusions: Detailed anatomical scan and counselling should be done after FIUVV diagnosis. The fetal surveillance should be increased to look for major dilatation thombus or FGR. Longer analysis on the large population is needed to study the association of controls with the outcome. Also, long term studies are needed to for any delayed consequences affecting the adult life of these fetuses.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.